搜索
 > 【ALK-1】重组蛋白信息

ALK-1信息

英文名称:Activin receptor-like kinase 1
中文名称:激活素受体样激酶-1
靶点别称:TGF-B superfamily receptor type I,ACVRLK1 ,Activin receptor-like kinase 1,ALK-1,ACVRL1,ALK1,TSR-I,Serine/threonine-protein kinase receptor R3,SKR3
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

ALK-1产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
AL1-H5227
Human
Recombinant Human ALK-1 / ACVRL1 Protein

ALK-1 分子别名

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

ALK-1 分子背景

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

ALK-1 参考文献

ALK-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Dalantercept ACE-041 临床二期 Acceleron 肾细胞癌, 实体瘤, 多发性骨髓瘤, 肝细胞癌, 头颈癌 详情
Ascrinvacumab PF-03446962; PF-3446962; PF-3-446-962 临床二期 辉瑞, 杜克大学医学中心, Fondazione IRCCS Istituto Nazionale dei Tumori, 苏州开拓药业 尿生殖系统癌症, 肝细胞癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定